Results 131 to 140 of about 4,697 (156)

An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL. [PDF]

Blood Adv
Shadman M, Tam CS, Brander DM, Lefebure M, Yang K, Xu S, Tian T, Kuptsova-Clarkson N, Williams R, Hirata J, Munir T.   +10 more
europepmc   +1 more source

Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies. [PDF]

Cell Biol Toxicol
Wang P, Fu H, Wu J, Li R, Cao L, Xu RA, Lin W.   +6 more
europepmc   +1 more source

Economic Evaluation of Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. [PDF]

Appl Health Econ Health Policy
Woudberg R, Sinanovic E.
europepmc   +1 more source

Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review. [PDF]

Ther Adv Hematol
Al-Mashdali AF, Abdelraof MO, Mukhtar RM, Mohamed SF.   +3 more
europepmc   +1 more source

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies. [PDF]

Int J Mol Sci
Meza K, Barrientos Risso C, Shah A, Romagnoli C, Sandoval J, Brauchle Y, Lyubimova A, Santos L, Goya Balaguer E, Barrientos J.   +9 more
europepmc   +1 more source

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia. [PDF]

Future Oncol
Shadman M, Chanan-Khan A, Campbell D, Xue M, Massoudi M, Williams R, Yang K, Tam CS.   +7 more
europepmc   +1 more source

Rare CNS manifestation of high-risk CLL with excellent response to triplet targeted therapy. [PDF]

Leuk Res Rep
Swaminathan A, Nathany S, Singh S, Gupta A, Sen IB, Garg P, Kothari A, Verma K, Dua V, Bhargava R.   +9 more
europepmc   +1 more source

Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada. [PDF]

J Mark Access Health Policy
Crean B, Parry D, Horsfield A, Ryan J, Oraiopoulos N.   +4 more
europepmc   +1 more source

Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. [PDF]

Front Oncol
Martinez-Gamboa DA, Beas FF, Moreno-Cortes E, Swanson LA, Mangold AR, Vargas F, Castro JE.   +6 more
europepmc   +1 more source

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12. [PDF]

Blood Adv
Laurenti L, Guglielmi F, Mosca A, Vitale C, Montalbano MC, Favrin G, Ferrarini I, Galitzia A, Pasquale R, Moratti M, Catania G, Murru R, Giannarelli D, Martino EA, Moia R, Zucchetto A, Tissino E, Autore F, Tomasso A, Stirparo L, Quaranta T, Abbate PL, Gattei V, Gaidano G, Gentile M, Krampera M, Farina G, Visentin A, Innao V, Varettoni M, Coscia M, Innocenti I.   +31 more
europepmc   +1 more source